Repligen (NASDAQ:RGEN) Hits New 52-Week High – Time to Buy?

Repligen Corporation (NASDAQ:RGEN) reached a new 52-week high on Wednesday . The stock traded as high as $179.87 and last traded at $177.8660, with a volume of 224928 shares trading hands. The stock had previously closed at $166.15.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on RGEN shares. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Wells Fargo & Company lifted their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. boosted their price objective on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $166.43.

Repligen Stock Up 5.9%

The firm has a market cap of $9.93 billion, a price-to-earnings ratio of 242.26, a PEG ratio of 3.04 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The business’s 50-day moving average is $144.29 and its 200-day moving average is $131.18.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new stake in Repligen during the 1st quarter valued at $262,000. Jones Financial Companies Lllp boosted its stake in Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after purchasing an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Bank of Nova Scotia grew its holdings in shares of Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after purchasing an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in shares of Repligen by 29.7% during the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.